<scp>MLL</scp>‐rearranged acute myeloid leukemia: Influence of the genetic partner in allo‐<scp>HSCT</scp> response and prognostic factor of <scp>MLL</scp> 3′ region <scp>mRNA</scp> expression

Burillo‐Sanz, Sergio; Morales‐Camacho, Rosario M.; Caballero‐Velázquez, Teresa; Carrillo, Estrella; Sánchez, Javier; Pérez-López, Olga; Soto, Inmaculada Pérez de; Campos, José Alejandro González; Prats‐Martín, Concepción; Bernal, Ricardo; Vargas, María Teresa

doi:10.1111/ejh.13037

Cited by 5 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, allo-HSCT remains the only therapy to cure high-risk KMT2A r AML patients [32]; however, different KMT2A genetic fusions have shown different prognostics. Data from Burillo-Sanz et al [33] showed that OS of patients undergoing allo-HSCT was longer for patients harboring KMT2A r fusions with MLLT3 and MLLT1 than the remaining KMT2A fusions. This result is in concordance with that obtained from other authors, in which rearrangements t (9;11) and t (11;19) showed a better outcome when subjected to allo-HSCT rather than t (6;11) and t (10;11), being extended to other types of KMT2A rearrangement [34].…”

Section: Discussionmentioning

confidence: 99%

Adult Acute Myeloid Leukemia with the KMT2A-Mixed Lineage Leukemia T10 Fusion: An Analysis of 10 Cases Showed Common Features and Frequent Mutations in the RAS Signaling Pathway

et al. 2021

View full text Add to dashboard Cite

Mixed lineage leukemia (MLL) T10 is a relatively rare partner for the KMT2A lysine (K)-specific methyltransferase 2A gene. The common features and coexisting mutations of acute myeloid leukemia (AML) patients with KMT2A-MLLT10 remain unknown. In this study, 10 adult AML patients with KMT2A-MLLT10 fusions were picked up from 496 AML patients by using RT-polymerase chain reaction (PCR) and/or fluorescence in situ hybridization, and then screened for mutations in the 49 genes panel with next-generation sequencing and PCR, followed by direct Sanger sequencing. Of the 10 unique individuals identified, 6 were male and 4 were female (M:F ratio, 1.5:1) with ages ranging from 19 to 52 years (median 39.5 years). Most (90%, 9/10) patients with KMT2A-MLLT10 were accompanied by additional mutations. Twelve mutated genes were detected, averaging 2.1 mutations per patient (range, 0–4). The most frequently mutated gene was NRAS (n = 5). Clinical and laboratory data pointed to common features: French American British-M5 subtype (n = 7), a high rate of relapse, and biomarkers CD33 (n = 10), CD117 (n = 9), CD13 (n = 8), and CD64 (n = 8). Overall, most patients harbored at least one mutation. A high incidence of mutations affecting the RAS signaling pathway or RAS regulating components was found in 50% (5/10) patients. The overall survival is about 12.0 months. Allogeneic-hematopoietic stem cell transplantation trends to improve survival in selected patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Adult Acute Myeloid Leukemia with the KMT2A-Mixed Lineage Leukemia T10 Fusion: An Analysis of 10 Cases Showed Common Features and Frequent Mutations in the RAS Signaling Pathway

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Similarly, histone methyltransferases can be dysregulated in AML. These include mutations in ASXL1 (5%), associated with relapsed AML 344 ; MLL1 (11q23) rearrangements (5-10%) with more than 80 partner genes 345 , including AF4, AF9, ENL, and ELL, which belong to and recruit the SEC complex and DOT1L to deposit H3K4me1 and H3K79me2 marks on active chromatin 346 ; and mutations in SETD2 (5%) 325 . Moreover, AML cases have shown histone acetyl-transferase CREBBP1 (CBP) and EP300 (p300) rearrangements with KAT6 (MOZ) 325,336 .…”

Section: Epigenetic Dysregulation In Acute Myeloid Leukaemiamentioning

confidence: 99%

Functional study of chromatin factors uncovers strong lineage determining roles and divergent behaviours between normal and malignant haematopoiesis

Goñi

View full text Add to dashboard Cite

Gracias a toda mi familia, mis tíos, primos y abuelos. Gracias yaya Carmen, se que desde el cielo siempre seguirás mis pasos.Gracias tato por confiar en que puedo con cada reto, por tu alegría, compromiso y criterio. Eres fundamental en mi vida.Gracias mamá y papá. Sois un gran ejemplo de trabajo, compromiso y unión. Gracias por cuidarme y acompañarme siempre. Este trabajo es para vosotros. 11 12 13 ABBREVIATIONS 3C Chromosome conformation capture 3D Three-dimensional Act1 Actin 1 ACTB Actin beta ACTL6A/B (BAF53A/B) Actin like 6A/B AEBP2 AE binding protein 2 AML Acute myeloid leukaemia AmpR Ampicillin resistance ARID1A/B (BAF250A/B) AT-rich interaction domain 1A/B ARID2 (BAF200) AT-rich interaction domain 2 Arp4-6/8 Actin-related protein 4-6/8 ASH2L Absent, small or homeotic disc-like ASXL1-3 Additional sex combs like 1-3 ATAC-seq Assay for transposase-accessible chromatin with high-throughput sequencing ATXN7L1-3 Ataxin 7 like 1-3 AUTS2 Autism susceptibility gene 2 protein B cell Lymphocyte B Ba (BASO) Basophil BAP1 BRCA1-associated protein 1 BAZ1A/B-2A/B Bromodomain adjacent to zinc finger domain 1A/B-2A/B BCL7A-C B-cell CLL/lymphoma 7 protein family member A-C BCOR/BCORL1 BCL6 B cell lymphoma 6 corepressor/BCL6 corepressor-like 1 BDF1 Bromodomain-containing factor 1 BFP Blue fluorescent protein BM Bone marrow bp Base pair BPTF Bromodomain PHD finger transcription factor BRD7/9 Bromodomain containing protein 7/9 BSA Bovine serum albumin C57BL/6J Cas9-neg (Wild-type) CAP-D2/D3/G/G2 Chromosome associated proteins D2/D3/G/G2 CAP-H/H2 Chromosome associated protein H Kleisin proteins Cas9 CRISPR-associated protein 9 cBAF Canonical BAF CBX2-8 Chromobox protein homolog 2-8 CCNC (CDK19) Cyclin-C CDCA5 (Sororin) Cell division cycle associated 5 CDK2AP1 (DOC1) Cyclin-dependent kinase 2 CDK2 associated protein 1 CDK8 Cyclin-dependent kinase 8 CECR2 Cat eye syndrome chromosome region protein 2 CF Chromatin factor CHD3 (Mi-2a)/CHD4 (Mi-2b)/CHD5 (KIAA0444) Chromodomain helicase DNA-binding protein 3-5 CHIP-seq Chromatin immunoprecipitation followed by sequencing CHRAC1 Chromatin accessibility complex subunit 1 CIMA Centre for Applied Medical Research CKIIa1/a2/b Casein kinase II alpha 1/alpha 2/beta CLP Common lymphoid progenitor COMPASS Complex of proteins associated with the Set1 CoREST REST corepressor CPM Counts per million cPRC1 Canonical PRC1 CRISPR Clustered regularly interspaced short palindromic repeats DC Dendritic cell RESULTS .

show abstract

Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia

Chi

Wang

2021

Hematology

View full text Add to dashboard Cite

MLL‐rearranged acute myeloid leukemia: Influence of the genetic partner in allo‐HSCT response and prognostic factor of MLL 3′ region mRNA expression

Abstract: We show that the MLL genetic partner could have implications in allo-HSCT response, and we propose three genes whose expression could be useful for the prognosis of this leukemia in patients undergoing allo-HSCT: 3' region of MLL, EVI1, and FLT3.

Cited by 5 publications

References 27 publications

Adult Acute Myeloid Leukemia with the <b><i>KMT2A-</i></b>Mixed Lineage Leukemia <b><i>T10</i></b> Fusion: An Analysis of 10 Cases Showed Common Features and Frequent Mutations in the RAS Signaling Pathway

Adult Acute Myeloid Leukemia with the <b><i>KMT2A-</i></b>Mixed Lineage Leukemia <b><i>T10</i></b> Fusion: An Analysis of 10 Cases Showed Common Features and Frequent Mutations in the RAS Signaling Pathway

Functional study of chromatin factors uncovers strong lineage determining roles and divergent behaviours between normal and malignant haematopoiesis

Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia

Contact Info

Product

Resources

About